Upholding its philosophy, “public’s health is Sinphar’s ideal” Sinphar Group has accompanied the public for almost 40 years. All these time, the company has always embraced its focus on “life, health, and technology” in developing therapeutic drugs, health care foods, and medical beauty products to provide the public with the best service for protecting their health and quality of life.

The parent company, Sinphar Pharmaceutical was inaugurated in 1977 in Yilan, Taiwan.Since 1997, the company started extending its global presence by first establishing its subsidiary CanCap Pharmaceutical in Canada to build its foundation for manufacturing and sales in North America. In 2002, Sinphar invested in China, establishing the Sinphar Tianli Pharmaceutical. Subsequently, the company established SynCore Biotechnology in Yilan in 2008 and then acquired ZuniMed Biotech in 2012.

Sinphar Group attaches equal importance to research, development, production and marketing. In addition to leveraging the marketing networks of its overseas subsidiaries to expand its business, Sinphar built its R&D Center in 2000 that satisfies ISO17025 standards. The group cultivated professional teams, purchased high-tech precision testing instruments, and developed the most advanced cell and molecular biology testing technologies, to build its status as an international company providing specialized, high-quality services.Thus far, Sinphar’s cancer drugs and other new drugs have been subjected to clinical trials in multiple countries worldwide. Moreover, Sinphar has started developing cooperative projects and engaging in product marketing. Improving human health and advancing toward globalization and internationalization are the stringent requirements and visions Sinphar impose upon itself!